Noile-Immune Biotech Inc. (TYO:4893)
77.00
-4.00 (-4.94%)
Nov 18, 2026, 10:49 AM JST
Noile-Immune Biotech Revenue
In the year 2025, Noile-Immune Biotech had annual revenue of 5.00M JPY, down -28.57%. That makes Noile-Immune Biotech the 47,419th largest company in the world by revenue and 3,878th in Japan.
Revenue
5.00M
Revenue Growth
-28.57%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
23
Market Cap
3.34B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.00M | -2.00M | -28.57% |
| Dec 31, 2024 | 7.00M | -309.00M | -97.78% |
| Dec 31, 2023 | 316.00M | -309.00M | -49.44% |
| Dec 31, 2022 | 625.00M | 525.00M | 525.00% |
| Dec 31, 2021 | 100.00M | 3.00M | 3.09% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Transgenic Group | 14.02B |
| Kohjin Bio | 4.38B |
| Human Metabolome Technologies | 1.48B |
| MEDINET | 998.00M |
| PRISM BioLab Co.,LTD | 737.27M |
| SUSMED,Inc. | 679.00M |
| Kringle Pharma | 442.00M |
| D. Western Therapeutics Institute | 140.90M |